MEMORANDUM OPINION

April 14, 2022 Wilmington, Delaware a ST , U.S. Circuit Judge:

On January 27, 2016, Plaintiffs Rosario Godreau-Rivera and Jose Rivera-Kercado (“Plaintiffs”) filed a lawsuit against Defendant Coloplast Corp. (“Defendant” or “Coloplast”) in multi-district litigation (“MDL”) then pending in the U:S. District Court for the Southern District of West Virginia. (See D.I. ^[1]) Plaintiffs asserted 17 counts arising from the injuries allegedly caused by Defendant’s Restorelle® DirectFix (““Restorelle”) polypropylene surgical mesh device implanted during Ms. Godreau-Rivera’s pelvic floor reconstructive surgery. (See D.I. ^[1] 4 13; D.I. 102 at 1) On September 26, 2019, after the time to conduct discovery was complete and the parties had filed motions to exclude expert testimony (“Daubert motions”) and motions for summary judgment in the MDL (see D.I. 80), Plaintiffs’ individual case was transferred to this Court. (See D.I. 67, 75) This Court denied all then-pending motions without prejudice to renew and set out procedures for the parties to file case-specific Daubert and summary judgment motions in this case. (See D.I. 87 at 4-5; D.I. 105 at 10-11) Pursuant to taese procedures, Defendant filed several Daubert and summary judgment motions, which are pending before the Court.! (See D.I. 101)

' After Defendant filed the opening brief in support of its case-specific Daubert and summary judgment motions, Plaintiffs filed a motion to strike Defendant’s motions, contending that Defendant had violated the Court’s procedures for renewing motions and had waived certain issues by failing to raise them in the MDL motions. (See D.I. 103, 104, 109, 110) The Court heard argument on the motion to strike and denied the motion. (See D.I. 118; D.I. 121 at 20) The Court, however, allowed the parties to address — in additional pages of the then-forthcoming answering and reply briefs of the pending Daubert and summary judgment motions — pertinent issues raised in the motion to strike, including the waiver issue. (See D.I. 118; D.I. 121 at 20-21)

The Court has reviewed the parties’ briefs and other materials submitted in connection with the pending motions. (See, e.g., D.I. 102, 122-24, 126, 128, 129, 132, 134, 136-39)? The Court also heard oral argument via teleconference on April 27, 2021. (See D.I. 133) (“Tr.”) 1. LEGAL STANDARDS A. Daubert Motions In Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 597 (1993), the Supreme Court explained that Federal Rule of Evidence 702 creates “a gatekeeping role for the [trial] judge” in order to “ensur[e] that an expert’s testimony both rests on a reliable foundation and is relevant to the task at hand.” Rule 702(a) requires that permissible expert testimony “help the trier of fact to understand the evidence or to determine a fact in issue.” Expert testimony is admissible only if “the testimony is based on sufficient facts or data,” “the testimony is the product of reliable principles and methods,” and “the expert has reliably applied the principles and methods to the facts of the case.” Fed. R. Evid. 702(b)-(d). There are three distinct requirements for admissible expert testimony: (1) the expert must be qualified; (2) the opinion must be reliable; and (3) the expert’s opinion must relate to the facts. See generally Elcock v.

* Given the size of the MDL and the numerous remand proceedings that have already occurred in other courts, it is unsurprising that essentially every issue raised in Defendant’s motions has been litigated in other courts — usually, quite extensively. The Court directed the parties to prepare a table that, as of May 2021, listed every decision of the MDL court and the remand courts that addressed one or more of the Daubert issues raised in Defendant’s pending motions. (See D.I. 137; see also D.I. 138 (Defendant advising Court in February 2022 of supplemental authority granting motions to exclude opinions of Drs. Mays and Pence); D.I. 139 (Plaintiffs advising Court in February 2022 of five opinions permitting Dr. Mays’ testimony and seven opinions permitting Dr. Rosenzweig’s testimony)) The Court has found this table (as well as the parties’ subsequent filings), and the decisions summarized, to be helpful in its analysis. Although none of the opinions listed in the table are binding on this Court, many are persuasive, and the Court has benefited from considering each of them. Many are cited elsewhere in this Memorandum Opinion.

Kmart Corp., 233 F.3d 734, 741-46 (3d Cir. 2000). Rule 702 embodies a “liberal policy of admissibility.” Pineda v. Ford Motor Co., 520 F.3d 237, 243 (3d Cir. 2008).

B. Summary Judgment Motion

“The court shall grant summary judgment if the movant shows that there is no genuine dispute as to any material fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a). The moving party bears the burden of demonstrating the absence of a genuine issue of material fact. See Matsushita Elec. Indus. Co., Ltd. v. Zenith Radio Corp., 475 U.S. 574, 586 n.10 (1986). An assertion that a fact cannot be — or, alternatively, is — genuinely disputed must be supported either by citing to “particular parts of materials in the record, including depositions, documents, electronically stored information, affidavits or declarations, stipulations (including those made for the purposes of the motion only), admissions, interrogatory answers, or other materials,” or by “showing that the materials cited do not establish the absence or presence of a genuine dispute, or that an adverse party cannot produce admissible evidence to support the fact.” Fed. R. Civ. P. 56(c)(1)(A) & (B). If the moving party has carried its burden, the nonmovant must then “come forward with specific facts showing that there is a genuine issue for trial.” Matsushita, 475 U.S. at 587 (internal quotation marks and emphasis omitted). The Court will “draw all reasonable inferences in favor of the nonmoving party, and it may not make credibility determinations or weigh the evidence.” Reeves v. Sanderson Plumbing Prods., Inc., 530 U.S. 133, 150 (2000).

To defeat a motion for summary judgment, the non-moving party must “do more than simply show that there is some metaphysical doubt as to the material facts.” Matsushita, 475 U.S. at 586; see also Podohnik v. U.S. Postal Serv., 409 F.3d 584, 594 (3d Cir. 2005) (stating party opposing summary judgment “must present more than just bare assertions, conclusory allegations or suspicions to show the existence of a genuine issue”) (internal quotation marks omitted). However, the “mere existence of some alleged factual dispute between the parties will not defeat an otherwise properly supported motion for summary judgment;” and a factual dispute is genuine only where “the evidence is such that a reasonable jury could return a verdict for the nonmoving party.” Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 247-48 (1986). “If the evidence is merely colorable, or is not significantly probative, summary judgment may be granted.” Jd. at 249-50 (internal citations omitted); see also Celotex Corp. v. Catrett, 477 U.S. 317, 322 (1986) (stating entry of summary judgment is mandated “against a party who fails to make a showing sufficient to establish the existence of an element essential to that party’s case, and on which that party will bear the burden of proof at trial”). Thus, the “mere existence of a scintilla of evidence” in support of the non-moving party’s position is insufficient to defeat a motion for summary judgment; there must be “evidence on which the jury could reasonably find” for the non-moving party. Anderson, 477 U.S. at 252. I. DISCUSSION A. Daubert Motions Dr. Rosenzweig’s expert report does not reveal any experience, education, or knowledge about the appropriate testing a medical device manufacturer should perform on its mesh products prior to marketing. Although Plaintiffs contend that Dr. Rosenzweig “has substantial experience with testing genitourinary and pelvic medical devices” (id.), none of the listed product development projects Dr. Rosenzweig participated in has anything to do with mesh products or clinically relevant testing (see id. at 13 n.2). Dr. Rosenzweig is not qualified to provide expert opinions on the adequacy of Defendant’s testing of mesh products. See, e.g., Humleker v. Bos. Sci. Corp., 2020 WL 6870852, at *9 (M.D. Fla. Oct. ^[2], 2020) (excluding Dr. Rosenzweig’s opinion that “Defendant should have conducted clinically relevant testing to determine if naturally occurring conditions in the vagina could cause polypropylene used in Defendant’s Mesh Products to alter inside the woman’s body”).

g. Safer Alternative Designs Defendant contends that the Court should exclude the opinions of Dr. Rosenzweig — and also of Dr. Garely — regarding safer alternative designs for the Restorelle mesh implant, arguing these opinions are “unsupported, speculative, and irrelevant.” (D.I. 102 at 19) According to Defendant, the expert opinions on this point are “guesswork” lacking scientific support, and the alternative surgical procedures and non-mesh repair products pointed to by the experts are irrelevant because they are not “alternative product designs.” (/d. at 19-22) In response, Plaintiffs argue that Drs. Rosenzweig and Garely’s experience in the medical profession enables them to reliably opine on comparable design concepts and products, and that their opinions about safer alternative designs — including procedures and non-mesh products — are relevant to Plaintiffs’ claims. (See D.I. 122 at 14-15)

1]

This portion of Defendant’s motion will be denied. Drs. Rosenzweig and Garely’s opinions regarding safer alternative designs are relevant and sufficiently reliable. Under Delaware law, “[i]t is legally possible for a plaintiff to prove [a] defective design even if no alternative design has been identified.” Barba v. Carlson, 2014 WL 1678246, at *5 (Del. Super. Ct. Apr. 8, 2014). This makes the opinions relevant.

Moreover, these opinions are based on these experts’ experience with mesh products and their review of medical literature and other product materials (see, e.g., D.I. 102 Ex. 6 at 15; D.I. 123 Ex. I), and on their conclusions that the existing materials and designs of the Restorelle mesh implant have contributed to complications and tissue damages (see, e.g., D.I. 102 Ex. 6 at 15; 122 Ex. H at 14-16, 29-33). Defendant’s contention that injuries might still occur using an alternative procedure or product does not warrant the exclusion of Drs. Rosenzweig and Garely’s opinions. (See D.I. 102 at 19; see also Dorgan v. Ethicon, Inc., 2020 WL 5367062, at *3 (W.D. Mo. Sept. 8, 2020)) The challenges to the scientific rigor of Drs. Rosenzweig and Garely’s opinions (see D.I. 102 at 19-20) go to the weight the factfinder may choose to give these opinions, not their admissibility.

repair surgery. He has personally examined, diagnosed, and treated over 100 patients with mesh complications. He has also authored multiple peer-reviewed articles, including articles relating to mesh products, and four book chapters on pelvic floor disorders. (See D.I. 122 Ex. H at 1-5) His experience in pelvic floor surgery and his familiarity with the complications caused by mesh products render him qualified to provide opinions on the design of mesh products.

Defendant next argues Dr. Garely cannot opine that the Restorelle implant has a “defective design” because that opinion “impinges upon the province of the jury to make findings of fact.” (D.I. 102 at 14) An expert opinion “is not objectionable just because it embraces an ultimate issue.” Fed. R. Evid. 704. Defendant also insists that Dr. Garely’s opinions relating to the design features of the Restorelle implant are unreliable because they are not “based on the methods and procedures of science.” (D.I. 102 at 15) The Court, however, finds that Dr. Garely’s opinions are well-grounded in both his clinical experience in treating mesh complications (see D.I. 122 Ex. H at 1-5), and in his review of Defendant’s internal documents on mesh products (see D.I. 123 Ex. I).

Hence, this portion of Defendant’s motion will be denied.

b. Adequacy Of Defendant’s IFUs Defendant seeks to exclude Dr. Garely’s opinions regarding the adequacy of its IFUs. (See D.I. 102 at 15-17) According to Defendant, since Dr. Garely, by his own admission, is not an expert in the areas of product warnings, product labeling, or regulation compliance, he cannot offer opinions about “what an IFU should or should not include,” or “whether an IFU comp.ies with regulatory standard.” In re C.R. Bard, Inc., Pelvic Repair Sys. Prods. Liab. Litig., 2018 WL 4212409, at *4 (S.D.W. Va. Sept. ^[4], 2018); see also In re Ethicon Inc. Pelvic Repair Sys. Prod. Liab. Litig., 2016 WL 4582209, at *3 (S.D.W. Va. Sept. ^[1], 2016).

Plaintiffs counter that Dr. Garely’s undisputed expertise in female pelvic health and reconstructive surgery makes him “fully qualified to opine on the medical facts and science regarding the risks and benefits of drugs and to compare that knowledge with what was provided in the text of labeling and warnings.” Jn re Yasmin & YAZ (Drospirenone) Mktg., Sales Practices, & Prods. Liab. Litig., 2011 WL 6301625, at[*11] -13 (S.D. Ill. Dec. 16, 2011); see also Huskey v. Ethicon, Inc., 29 F. Supp. 3d, 691, 719 (S.D.W. Va. 2014) (finding urologist qualified to testify about risks of implanting product and whether those risks were adequately expressed on product’s IFU).

In the Court’s view, the parties’ competing positions are not truly conflicting. The Court finds the reasoning in Wise v. C.R. Bard, Inc., 2015 WL 521202, at[*14] (S.D.W. Va. Feb. 7, 2015), instructive here:

I have concluded that although Dr. Ostergard is not qualified to opine on FDA regulations and whether a product label satisfies those regulations, he is qualified to evaluate Bard’s warnings based on his knowledge of and experience with the risks of the Avaulta.... I reach the same conclusion with respect to Dr.

Raybon. Dr. Raybon has no demonstrated experience in the requirements for product labeling, and as such, he may not testify as to what the Avaulta label should or should not have included under the law. However, as an experienced urogynecologist, he may testify about the risks he perceives that the Avaulta poses to patients and then opine that the Avaulta IFU did not convey those risks.

The court in Arevalo, 2020 WL 3958505, at *5, embraced the same? anztlysis:

The Court finds that Dr. Garely is qualified to testify about the risks associated with the device and whether those risks were adequately expressed in the device’s IFU, how physicians use IFUs, and the type of information typically included in IFUs, but he is not qualified to opine on whether an IFU complies with regulatory standards.

The Court will adopt the same approach here. Dr. Garely will be permitted to offer opinions as to whether Defendant’s IFUs provided adequate information about the risks associated with mesh implants, but he may not offer opinions as to what Defendant was, for example, “obligated” to include in its IFUs. (See, e.g., DI. 122 Ex. H at 23) (“If Coloplast knew or believed . . . , it was obligated to so advise the physician users of the products.”) Accomplishing this result means granting in part and denying part this portion of Defendant’s motion.

c. General Causation Defendant contends that Dr. Garely’s general causation opinions should be excluded because they are not based on either “sufficient facts and data” or “reliable principles and methods.” (D.I. 102 at 17) According to Defendant, Dr. Garely’s “personal experience with the Restorelle is virtually non-existent,” adding that the publications on which his opinions rely are not “specific to Restorelle.” (/d. at 17-18) This portion of Defendant’s motion will be denied because the Court finds Dr. Garely’s general causation opinions are sufficiently reliable. In his report, Dr. Garely states that his general causation opinions are based on his personal observation and treatment of “patients that have experienced . . . complications associated to the transvaginal placement of polypropylene pelvic organ prolapse mesh,” and “[t]he published medical literature [that] reports these same types of complications.” (D.I. 122 Ex. H at 35-36) While Dr. Garely may not have personal experience with the Restorelle product specifically, he has extensive clinical experience with polypropylene-containing pelvic mesh products generally. It is not unreliable for him to extrapolate his observations of the complications associated with polypropylene-containing pelvic mesh products in general to those associated specifically with the Restorelle implant. (See D.I. 122 at 21; see also D.I. 123 Ex. J at 299-300 (“I don’t know necessarily what [mesh products the patients] have. It doesn’t change the approach or the outcome.”)) The scientific rigor of Dr. Garely’s opinions is a proper subject for cross-examination and presents an issue going to the weight, not the admissibility, of the opinions.

d. FDA’s Position On Surgical Mesh Products Defendant seeks to preclude Dr. Garely from testifying about the FDA’s position on surgical mesh products. (See D.I. 102 at 18) At deposition, Dr. Garely repeatedly asserted that “the FDA agrees” with his opinions on the use of surgical mesh implants for transvaginal repair of pelvic organ prolapse. (See, e.g., id. Ex. ^[2] at 58) (“I do not believe them to be safe, and this is why I don’t, and I have been now validated, I guess, by the FDA, who also does not believe them to be safe.”) Defendant contends that Dr. Garely is not qualified to render an opinion on the FDA’s position and that his opinions on this topic are irrelevant and unhelpful. (See id. at 18-19) Plaintiffs acknowledge Dr. Garely “does not opine that he is an FDA regulatory process expert, nor does he set forth the FDA’s position on surgical mesh,” but insist that Dr. Garely should be permitted to testify that “he and the FDA are in agreement on the safety of transvaginal mesh products.” (D.I. 122 at 22) This portion of Defendant’s motion will be granted. Dr. Garely will be precluded from testifying about the FDA’s position on surgical mesh products, including that “he and the FDA are in agreement.” He is not qualified to render opinions about the FDA’s position.’

7 Whether the jury will hear anything about the FDA’s position is not the subject of any pending motion. If Plaintiffs have some other witness through whom they believe they can admit such evidence, this issue may become the subject of a motion in limine or an objection at trial.

contrary to Defendant’s contention, that he reviewed literature specifically concerning the Restorelle mesh implant. (See D.I. 123 Ex. L at 18-19) Dr. Michaels also explained that his opinions would not differ in a Restorelle case from those in cases involving other polypropylene mesh products. (See D.I. 122 at 24; see also D.I. 123 Ex. L at 68) Additionally, Dr. Michaels states in his report that he reviewed Ms. Godreau-Rivera’s medical records and evaluated slides prepared from her vaginal mesh pathology specimen. (See D.I. 102 Ex. 17 at 1) Dr. Michaels also considered and ruled out several alternative causes. (See Tr. at 56; see also D.I. 102 Ex. 17 at 8) Thus, Dr. Michaels’ specific causation opinions are based on reliable pathological methodology.

Defendant’s challenges with respect to the scientific soundness of Dr. Michaels’ opinions, including the alleged failure to account for the characteristics of Restorelle (see D.I. 128 at 14-15), and the purported insufficiency of Dr. Michaels’ differential diagnosis (see Tr. at

59-62), go to the weight the factfinder may accord to Dr. Michaels’ opinions, not their admissibility. See, e.g., Tucker v. Ethicon, Inc., 2021 WL 825921, at *4 (E.D. Mo. Mar. ^[4], 2021) (“Dr. Michaels’ case-specific opinions appear to be grounded on his general opinions and his review of Plaintiff's medical history, tissue samples, and explanted pelvic mesh. These are sufficiently reliable for purposes of Daubert, even if Dr. Michaels did not use a control sample.”); Townsend, 2021 WL 304555, at *1 (“Dr. Michaels reviewed [the plaintiffs] medical records, slides of tissue specimens explanted from [the plaintiff], internal Ethicon documents, scientific literature, and deposition testimony from this case. ... The defendants’ challenges go to the weight of Dr. Michaels’ testimony, not its admissibility, and the defendants may cross examine him on these points.”). Accordingly, this portion of Defendant’s motion will be denied.

release of oxidizing agents and persistent foreign body response. (See D.I. 122 at 29; see also D.I. 123 Ex. N at 233-34) The parties’ competing interpretations of scientific studies, as well as their conflicting positions over whether these studies support the factual predicate of Dr. Mays’ opinions on polypropylene degradation in vivo, present a dispute to be resolved by the factfinder and go to the weight, not the admissibility, of these opinions. See, e.g., Nunez v. Coloplast Corp., 2020 WL 2315077, at *4 (S.D. Fla. May 11, 2020) (“[A]s to the argument that there are authorities that ‘flatly contradict’ Dr. Mays’s opinions, . . . this [is] an issue that goes to weight and credibility.”).

Defendant also contends that Dr. Mays’ opinions are unreliable because he relied on an article containing the testing data he had included in his expert report submitted in a different MDL, a report which “was excluded on several occasions,” and he failed to account for some “key differences” between the polypropylene mesh products made by other manufacturers and the ones made by Defendant. (D.I. 102 at 31) In the Court’s view, however, Dr. Mays’ opinions — which are based on his experience, training, and education in polymer science, and his review of scientific literature and documents on Defendant’s polypropylene mesh products (see D.I. 122 at 28) — are sufficiently reliable to meet the requirements of Rule 702. The purported differences between Defendant’s polypropylene products and those of other manufacturers do not render Dr. Mays’ opinions unreliable. See In re Ethicon Inc. Pelvic Repair Sys. Prod. Liab. Litig., 2016 WL 4958282, at *2 (S.D.W. Va. Aug. 25, 2016) (“I disagree that the supposed distinction between Prolene specifically and polypropylene generally renders studies on the latter unhelpful when discussing the former.”). Accordingly, this portion of Defendant’s motion will be denied.

YD c. Linking Degradation To Medical Complaints Defendant contends Dr. Mays is not qualified to offer opinions regarding the medical complications allegedly caused by the degradation of polypropylene mesh. (See D.I. 102 at 32) Plaintiffs counter that Dr. Mays, a polymer expert with expertise in biomaterials, should be allowed to opine on “the clinical significance of [polypropylene] degradation.” (D.I. 122 at 31) During oral argument, Plaintiffs clarified that Dr. Mays would only offer “general opinions about . . . the producing of a tissue response to the oxidizing of the polypropylene in the tissue;” he will not testify to “something of clinical significance specifically in [Ms. Godreau-Rivera]” or “what the patient would subjectively experience.” (Tr. at 70-71) The Court will deny this portion of Defendant’s motion.

Dr. Mays’ extensive experience in polymer science, and particularly in biomaterials, renders him qualified to testify generally about tissue responses caused by oxidative degradation of polypropylene mesh products, even though he is not a medical doctor and does not examine or treat patients. See, e.g., Nunez, 2020 WL 2315077, at *3; Wise, 2015 WL 521202, at *9.

d. Oxidative Degradation Results In Reduction Of Mechanical Properties Of Surgical Mesh Implants Defendant seeks to exclude Dr. Mays’ opinions that oxidative degradation results in a breakdown of mechanical properties of polypropylene mesh products, on the grounds that (1) Dr. Mays is not qualified to quantify the breakdown of mechanical properties, and (2) his opinions are based on an assumption unsupported by any published study. (See D.I. 102 at 33) This portion of Defendant’s motion will be denied.

The Court agrees with Plaintiffs that Dr. Mays possesses the requisite qualifications and that his opinions are sufficiently reliable. Dr. Mays’ inability to quantify the degree of mechanical breakdown does not prevent him from providing opinions, in a qualitative sense, that reduction in mechanical properties and increase in stiffness of the polypropylene mesh products occur. (See D.I. 122 at 32; see also Arevalo, 2020 WL 3958505, at *8) Dr. Mays’ opinions rest on a reliable foundation as they are based on his extensive experience in polymer science and his review of scientific publications. The fact that he was not able to point to a specific article demonstrating a breakdown in mechanical properties of the polypropylene mesh products goes to the weight, not the admissibility, of his opinions.

e. Medical Safety Data Sheets Defendant first contends that Dr. Mays should be precluded from giving opinions on the alleged toxicity or irritability of polypropylene resin or antioxidants. (See D.I. 102 at 33-34) This portion of Defendant’s motion will be granted. The Court agrees with Defendant that since Dr. Mays is not a toxicologist, he is not qualified to offer opinions on the toxicity of materials. See, e.g., Arevalo, 2020 WL 3958505, at *8; Bayless, 2020 WL 10058191, at *5.

Defendant next seeks to exclude Dr. Mays’ opinions on the oxidative degradation of the finished products in vivo, arguing that the information on the Medical Safety Data Sheets (“MSDS”) for raw materials is not a reliable basis for Dr. Mays’ opinions with respect to the finished products. (See D.I. 102 at 34) This portion of Defendant’s motion will be denied. Dr. Mays has adequately explained the connection between the MSDS for raw materials and his opinions on the oxidative degradation of the finished products. (See D.I. 123 Ex. M at 29-34) Thus, his reliance on the raw materials MSDS does not render his opinions regarding the finished products unreliable. See, e.g., Arevalo, 2020 WL 3958505, at *8; Wise, 2015 WL 521202, at[*11] . Defendant’s criticisms on these points go to the weight and not the admissibility of these opinions.

Defendant also seeks to exclude Dr. Mays’ testimony that “impermissibly inject[s] corporate state of mind or intent.” (D.I. 102 at 34) Since Plaintiffs agree that Dr. Mays will not testify on Defendant’s “state of mind, corporate conduct, and legal conclusions” (D.I. 122 at 33), this portion of Defendant’s motion is moot and, therefore, will be denied.

clinical trials before incorporating mesh materials into a surgical product.” Sanchez, 2014 WL 4851989, at[*34] . Contrary to Defendant’s contention, the non-binding nature of industry standards does not compel a conclusion that Dr. Pence’s premarket testing opinions based on them are unreliable. See Heatherly v. Bos. Sci. Corp., 2018 WL 3797507, at *5-6 (S.D.W. Va. Aug. 9, 2018); see also Lees v. Carthage Coll., 714 F.3d 516, 525 (7th Cir. 2013) (finding that whether international guidelines are controlling in industry is not “the relevant question for admissibility purposes”).

The Court is further unpersuaded by Defendant’s argument that Dr. Pence’s opinions are unreliable because she “simply summarizes comments from various sources about clinical testing and then jumps to her opinion that Coloplast’s device testing was inadequate.” (D.I. 102 at 39) By relying on her review of a voluminous amount of peer-reviewed scientific articles, deposition testimony, government codes and regulations, clinical trial materials, and Defendant’s internal documents, Dr. Pence has sufficiently demonstrated that her opinions are a product of a soundly grounded methodology. (See generally D.I. 124 Ex. P at 82-113) c. Adequacy Of Post-Market Surveillance Plaintiffs do not address this issue in their brief and conceded during oral argument that the Court can apply the rulings of other courts that have excluded Dr. Pence’s post-market surveillance opinions. (See Tr. at 85-86) The Court will grant this portion of Defendant’s motion.

B. Motion For Summary Judgment®

1. Claims Based On Specific Causation

This portion of Defendant’s motion for summary judgment is based solely on Plaintiffs’ supposed inability to adduce expert evidence to establish specific causation. (See D.I. 102 at 42) In other words, the motion turns entirely on Defendant’s related Daubert motions. As the Court has denied the pertinent portions of those Daubert motions — and has ruled that Drs. Rosenzweig and Michaels’ specific causation opinions are admissible — Defendant’s motion for summary judgment with respect to all of Plaintiffs’ claims based on specific causation will be denied.

2. Negligent Failure To Warn (Part Of Count I)

The parties agree that Delaware’s “learned intermediary” doctrine applies to Plaintiffs’ negligent failure to warn claim. (See D.I. 102 at 44; D.I. 122 at 42) “The learned intermediary doctrine provides for an exception to the general rule that a manufacturer of a [medical device] owes a duty to warn the consumer directly concerning the risks associated with the [device].” Lacy v. G.D. Searle & Co., 567 A.2d 398, 399 (Del. 1989). The doctrine “acts as an affirmative defense.” Hagan v. Bos. Sci. Corp., 2021 WL 1921893, at *6 (Del. Super. Ct. May 12, 2021). Hence, a manufacturer of a prescription medical device satisfies its duty to provide an appropriate warning about the device “when it gives the patient’s physician the necessary information to be disseminated to the patient.” Zacy, 567 A.2d at 399. The “learned intermediary” doctrine is inapplicable if a warning is “inadequate as a matter of law.” Evans v.

8 Defendant has moved for summary judgment on “all of Plaintiffs’ claims.” (D.I. 102 at 40) Plaintiffs indicate in their brief that they will not pursue the following claims: manufacturing defect (Count III and part of Count I), fraudulent concealment (Count VIII), constructive fraud (Count IX), discovery rule, tolling and fraudulent concealment (Count X), negligent infliction of emotional distress (Count XII), unjust enrichment (Count XV), and all strict liability claims (Counts II-V). (See D.I. 122 at 40-42) Accordingly, the Court will grant Defendant’s motion for summary judgment with respect to these claims.

Johnson & Johnson Co., 2020 WL 616575, at *4 (D. Del. Feb. 10, 2020) (quoting Barba, 2014 WL 1678246, at *2). If the warning is not insufficient as a matter of law, the issue proceeds to “whether additional information or warnings would have made a difference to a reasonable learned intermediary.” Barba, 2014 WL 1678246, at *3. “If the warnings and information are found to be adequate, and additional warnings or information would not have affected the medical decisions of a reasonable physician, then the learned intermediary insulates the manufacturer from liability.” Jd.

Defendant contends that its motion for summary judgment should be granted because (1) the warning Defendant provided to Ms. Godreau-Rivera’s prescribing and implanting physician, Dr. Vakili, is adequate (see D.I. 102 at 44-45); and (2) Plaintiffs cannot establish proximate causation, since Dr. Vakili was “independently aware of the potential risks” for which Plaintiffs now seek recovery and a differently-worded warning would not have changed Dr. Vakili’s prescribing decision (see id. at 45-47). Plaintiffs dispute both grounds. (See D.I. 122 at 43-47) They further contend that Dr. Vakili’s “financial bias” creates fact issues precluding summary judgment. (See id. at 47-49) The Court finds there is a genuine dispute of material fact over both the adequacy of the warning and proximate cause. A reasonable juror, taking all the evidence in the light most favorable to Plaintiffs and drawing all reasonable inferences in their favor, could find that the warning Defendant provided to “learned intermediaries” like Dr. Vakili was insufficient and, additionally, could also find that a different warning could have caused Dr. Vakili to act materially differently. Accordingly, and as more fully set out below, Defendant’s motion for summary judgment with respect to Plaintiffs’ negligent failure to warn claim will be denied.

I6 a. Adequacy Of Warning Defendant argues “the undisputed record evidence establishes that Coloplast provided accurate, clear, and unambiguous warnings about the potential risks associated with Restorelle in the accompanying IFU.” (D.I. 102 at 44) In particular, Defendant insists that the Restorelle IFU warned of each of the risks of developing each of the problems Ms. Godreau-Rivera has allegedly suffered. (See id. at 45) Relying primarily on Dr. Rosenzweig’s expert report, Plaintiffs counter that Defendant’s IFU “did not include sufficient information to advise physicians on the permanency, frequency, and severity of the complications that can arise from the use of its devices,” and further that Defendant “significantly downplayed the risks that it actually did list in its IFU.” (D.I. 122 at 43-44; see also id. Ex. F at 43-48) In its reply brief, Defendant argues that “‘so long as the manufacturer warned the physician about the injuries plaintiff complained of, the learned intermediary doctrine bars a failure-to-warn claim as a matter of law,” citing Lacy, 567 A.2d at 401. (D.I. 128 at 22) Defendant’s reliance on Lacy is misplaced. Lacy does not hold that a medical device provider’s obligation to warn a learned intermediary is discharged as long as the label mentions the types of injury of which a plaintiff complains, regardless of the injury’s “permanency, frequency, and severity.” Moreover, here the Court agrees with Plaintiffs that they have introduced sufficient evidence — including expert opinions the Court has found admissible — to create a genuine dispute of material fact as to whether the warnings provided by the Restorelle IFU are adequate. See Hagan, 2021 WL 1921893, at *6 (“The issue of whether adequate warnings were issued is factual and is usually resolved by the trier of fact.”’).

DFT b. Proximate Cause Defendant first contends that, prior to Ms. Godreau-Rivera’s implantation surgery, Dr. Vakili was independently aware of the “well-publicized” risks associated with Restorelle. (See D.I. 102 at 45-46) According to Defendant, this independent knowledge was obtained, at least in part, “through reading medical literature and FDA safety communications.” (/d. at 46) The record, however, reveals a genuine dispute of material fact as to whether the risks about Restorelle known to Dr. Vakili at the pertinent time would include the risks that Dr. Rosenzweig opines should have been included in the Restorelle IFU.

Defendant further argues that a differently-worded warning would not have changed Dr. Vakili’s prescribing decision. (See id. at 46-47) The Court finds, however, a genuine dispute of material fact as to whether Dr. Vakili’s prescribing decision would have remained the same had he received additional warnings about the fitness of Restorelle for human implantation. Dr. Vakili testified at his deposition:

Q: Yeah. If the company told you that polypropylene is not meant for human — permanent human implantation, would you continue to use polypropylene mesh?

A: I have to think about the answer to that question because it seems a little leading. So if the company said polypropylene as a material is not meant for human consumption?

Q: Implantation?

A: Implantation. If I was told that by the company, would I not use it?

Q: Yes.

A: I would take it into consideration, but I’m not sure it would totally inform my decision.

Q: Why wouldn’t it totally inform your decision?

IR

A: Because I would look at the body of medical literature that exists regarding products of that material before I made a final decision.

124 Ex. Q at 129-30) (emphasis added) Since Dr. Vakili did not unequivocally state that he would not have changed his prescribing decision, a reasonable factfinder could conclude that Dr. Vakili — after taking “into consideration” the hypothesized manufacturer warnings that polypropylene mesh is unfit for human implantation — may have come to a different prescribing decision. See, e.g., Humleker, 2020 WL 6870852, at[*16] (denying motion for summary judgment when implanting physician suggested that “she would have wanted additional information” regarding the safety of implanting polypropylene in human body).

The situation here is distinguishable from those presented in cases cited by Defendant (see D.I. 128 at 25), in which courts granted motions for summary judgment when physicians provided unequivocal testimony that they would not have changed their prescribing decisions — testimony Dr. Vakili did not give in this case.” Thus, the genuine factual dispute over proximate cause provide a further basis for denying Defendant’s motion for summary judgment with respect to Plaintiffs’ negligent failure to warn claim.'°

In supplemental authority submitted by Defendant (see D.I. 136), Salinero v. Johnson & Johnson, 995 F.3d 959, 966 (11th Cir. 2021), the Eleventh Circuit affirmed the district court’s grant of summary judgment to a defendant based, in part, on the implanting physician being “clear that an IFU containing more information on the risks posed by Artisyn Y-Mesh would not have altered his decision to use the implant in [the plaintiffs] surgery.” This authority does not help Defendant because the record is devoid of such a statement by Dr. Vakili. The Court need not reach Plaintiffs’ additional argument that Dr. Vakili’s financial bias creates fact issues precluding summary judgment. (See D.I. 122 at 47-49) 3. Breach Of Express Warranty (Count VI)

Under Delaware law, to prevail on a breach of express warranty claim, “the buyer must prove: (1) the existence of an express . . . warranty, (2) a breach of the defendant’s express .. . warranty, (3) a causal connection between the defendant’s breach and the plaintiff's injury or damage, and (4) the extent of loss proximately caused by the defendant’s breach.” Driscoll v. Automaxx, 2016 WL 5107066, at *2 (Del. Com. Pl. Apr. 27, 2016). An express warranty may arise in three ways:

(a) Any affirmation of fact or promise made by the seller to the buyer which relates to the goods and becomes part of the basis of the bargain creates an express warranty that the goods shall conform to the affirmation or promise.

(b) Any description of the goods which is made part of the basis of the bargain creates an express warranty that the goods shall conform to the description.

(c) Any sample or model which is made part of the basis of the bargain creates an express warranty that the whole of the goods shall conform to the sample or model.

6 Del. C. § 2-313(1). Defendant contends that Plaintiffs’ breach of express warranty claim fails because there is “no evidence that Coloplast made any express warranties to [Ms. Godreau-Rivera] as to the safety or effectiveness of Restorelle.” (D.I. 102 at 47) The Court agrees with Defendant.

Plaintiffs ground their express warranty theory on Defendant’s “assurances to the general public, hospitals, and health care professionals that its mesh products were safe and fit for their intended purpose.” (D.I. 122 at 51) However, it is undisputed that Ms. Godreau-Rivera “has never had any contact or conversation with anyone from Coloplast or seen any advertisements, brochures, or websites from Coloplast.” (Compare D.I. 102 at 41 with D.I. 122 at 38; see also D.I. 102 at 47, id. Ex. 32 at 164, 167, 198) It follows that, therefore, Plaintiffs cannot establish Ms. Godreau-Rivera’s reliance on the purported “assurances” to enter into a bargain with Defendant. See, e.g., Barba, 2014 WL 1678246, at *5 (granting summary judgment because plaintiff testified “she neither received nor relied upon any Boston Scientific materials”); Dilenno v. Libbey Glass Div., Owens-lll., Inc., 668 F. Supp. 373, 376 (D. Del. 1987) (holding that plaintiff's claim for breach of expressed warranty must fail because “[t]here is no evidence in the record to suggest that [the plaintiff] ever saw the [defendant’s] catalog let alone relied on it when she purchased the [product]”).

Thus, Defendant’s motion for summary judgment with respect to Plaintiffs’ breach of express warranty claim will be granted.

punitive damages. Accordingly, the Court will deny Defendant’s motion for summary judgment with respect to punitive damages.

C. Waiver

Plaintiffs contend that Defendant failed to raise the following issues in the MDL motions and, thus, has waived them:

[1] it did not move to exclude the entirety of Dr. Rosenzweig’s specific causation opinions; [2] it did not move on Dr. Garely’s mesh design opinions or his qualifications to opine on the adequacy of the warnings; [3] it did not challenge Dr. Mays’ qualifications on the material safety data sheet.

(D.I. 122 at 55) In response, Defendant shows that it has, in fact, raised the identified issues concerning Drs. Garely and Mays in their MDL motions. (See D.I. 128 at 30 (citing D.I. 129 Exs. 9-10)) The parties’ dispute with respect to waiver, then, is limited to Dr. Rosenzweig’s specific causation opinions. Because the Court has addressed the merits of this portion of Defendant’s Daubert motion — and, as explained above (see supra Part II.A.I.a), is denying this portion of the motion on the merits — the Court need not address the waiver issue. III. CONCLUSION An appropriate order follows.